{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:00:55Z","timestamp":1784959255689,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,24]]},"DOI":"10.7759\/cureus.113332","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:18:18Z","timestamp":1784956698000},"source":"Crossref","is-referenced-by-count":0,"title":["A Rare Case of Pleural Deciduoid Mesothelioma With Histological, Immunohistochemical, Fluorescent In Situ Hybridization, and Ultrastructural Findings"],"prefix":"10.7759","author":[{"given":"Hiroshi","family":"Sonobe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Omote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eito","family":"Niman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nabeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification","volume":"17","author":"Sauter JL","year":"2022","unstructured":"Sauter JL, Dacic S, Galateau-Salle F, et al.. The 2021 WHO classification of tumors of the pleura: advances since the 2015 classification. J Thorac Oncol. 2022, 17:608-22. 10.1016\/j.jtho.2021.12.014","journal-title":"J Thorac Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5652-y","article-title":"CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure","volume":"19","author":"Kettunen E","year":"2019","unstructured":"Kettunen E, Savukoski S, Salmenkivi K, et al.. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure. BMC Cancer. 2019, 19:507. 10.1186\/s12885-019-5652-y","journal-title":"BMC Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2017-0365-RA","article-title":"Malignant mesothelioma and its non-asbestos causes","volume":"142","author":"Attanoos RL","year":"2018","unstructured":"Attanoos RL, Churg A, Galateau-Salle F, Gibbs AR, Roggli VL. Malignant mesothelioma and its non-asbestos causes. Arch Pathol Lab Med. 2018, 142:753-60. 10.5858\/arpa.2017-0365-RA","journal-title":"Arch Pathol Lab Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2023-0304-RA","article-title":"Guidelines for pathologic diagnosis of mesothelioma: 2023 update of the consensus statement from the International Mesothelioma Interest Group","volume":"148","author":"Husain AN","year":"2024","unstructured":"Husain AN, Chapel DB, Attanoos R, et al.. Guidelines for pathologic diagnosis of mesothelioma: 2023 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2024, 148:1251-71. 10.5858\/arpa.2023-0304-RA","journal-title":"Arch Pathol Lab Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-198501000-00012","article-title":"Diffuse malignant peritoneal mesothelioma in a 13-year-old girl. Report of a case and review of the literature","volume":"9","author":"Talerman A","year":"1985","unstructured":"Talerman A, Montero JR, Chilcote RR, Okagaki T. Diffuse malignant peritoneal mesothelioma in a 13-year-old girl. Report of a case and review of the literature. Am J Surg Pathol. 1985, 9:73-80. 10.1097\/00000478-198501000-00012","journal-title":"Am J Surg Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2015-203211","article-title":"Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses","volume":"69","author":"Kawai T","year":"2016","unstructured":"Kawai T, Tominaga S, Hiroi S, et al.. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses. J Clin Pathol. 2016, 69:706-12. 10.1136\/jclinpath-2015-203211","journal-title":"J Clin Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800534","article-title":"Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity","volume":"19","author":"Yaziji H","year":"2006","unstructured":"Yaziji H, Battifora H, Barry TS, et al.. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol. 2006, 19:514-23. 10.1038\/modpathol.3800534","journal-title":"Mod Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2025.152475","article-title":"Utility and limitations of Merlin immunohistochemistry for mesothelioma diagnosis in tissue sections and cell blocks","volume":"77","author":"Nabeshima K","year":"2025","unstructured":"Nabeshima K, Hamasaki M, Furukawa T, Matsumoto S, Takizawa K, Adachi M, Goto Y. Utility and limitations of Merlin immunohistochemistry for mesothelioma diagnosis in tissue sections and cell blocks. Ann Diagn Pathol. 2025, 77:152475. 10.1016\/j.anndiagpath.2025.152475","journal-title":"Ann Diagn Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200002000-00015","article-title":"Mesotheliomas with deciduoid morphology: a morphologic spectrum and a variant not confined to young females","volume":"24","author":"Shanks JH","year":"2000","unstructured":"Shanks JH, Harris M, Banerjee SS, et al.. Mesotheliomas with deciduoid morphology: a morphologic spectrum and a variant not confined to young females. Am J Surg Pathol. 2000, 24:285-94. 10.1097\/00000478-200002000-00015","journal-title":"Am J Surg Pathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.105","article-title":"Deciduoid mesothelioma: report of 21 cases with review of the literature","volume":"25","author":"Ord\u00f3\u00f1ez NG","year":"2012","unstructured":"Ord\u00f3\u00f1ez NG. Deciduoid mesothelioma: report of 21 cases with review of the literature. Mod Pathol. 2012, 25:1481-95. 10.1038\/modpathol.2012.105","journal-title":"Mod Pathol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/crj.12599","article-title":"Deciduoid mesothelioma of the thorax: A comprehensive review of the scientific literature","volume":"12","author":"Paliogiannis P","year":"2018","unstructured":"Paliogiannis P, Putzu C, Ginesu GC, et al.. Deciduoid mesothelioma of the thorax: A comprehensive review of the scientific literature. Clin Respir J. 2018, 12:848-56. 10.1111\/crj.12599","journal-title":"Clin Respir J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12907-017-0051-2","article-title":"Malignant Deciduoid Mesothelioma: case presentation of an exceptional variant and review of the literature","volume":"17","author":"Khmou M","year":"2017","unstructured":"Khmou M, Echcharif S, Kabbaj R, Khannoussi BE. Malignant Deciduoid Mesothelioma: case presentation of an exceptional variant and review of the literature. BMC Clin Pathol. 2017, 17:13. 10.1186\/s12907-017-0051-2","journal-title":"BMC Clin Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.21037\/acr.2018.09.02","article-title":"Deciduoid type malignant pleural mesothelioma: a case report","volume":"2","author":"Okita R","year":"2018","unstructured":"Okita R, Nojima Y, Saisho S, et al.. Deciduoid type malignant pleural mesothelioma: a case report. AME Case Rep. 2018, 2:43. 10.21037\/acr.2018.09.02","journal-title":"AME Case Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/dc.10068","article-title":"Primary epithelial malignant mesothelioma of the pericardium with deciduoid features: cytohistologic and immunohistochemical study","volume":"26","author":"Reis-Filho JS","year":"2002","unstructured":"Reis-Filho JS, Pope LZ, Milanezi F, Balderrama CM, Serapi\u00e3o MJ, Schmitt FC. Primary epithelial malignant mesothelioma of the pericardium with deciduoid features: cytohistologic and immunohistochemical study. Diagn Cytopathol. 2002, 26:117-22. 10.1002\/dc.10068","journal-title":"Diagn Cytopathol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/dc.22902","article-title":"Deciduoid mesothelioma: cytologic presentation and diagnostic pitfalls","volume":"41","author":"Huang CC","year":"2013","unstructured":"Huang CC, Michael CW. Deciduoid mesothelioma: cytologic presentation and diagnostic pitfalls. Diagn Cytopathol. 2013, 41:629-35. 10.1002\/dc.22902","journal-title":"Diagn Cytopathol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910861","article-title":"Immunotherapy for treatment of pleural mesothelioma: current and emerging therapeutic strategies","volume":"25","author":"Chiec L","year":"2024","unstructured":"Chiec L, Bruno DS. Immunotherapy for treatment of pleural mesothelioma: current and emerging therapeutic strategies. Int J Mol Sci. 2024, 25:10861. 10.3390\/ijms251910861","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas P","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, et al.. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021, 397:375-86. 10.1016\/S0140-6736(20)32714-8","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2024.12.017","article-title":"Current drug therapy for pleural mesothelioma","volume":"63","author":"Imai H","year":"2025","unstructured":"Imai H. Current drug therapy for pleural mesothelioma. Respir Investig. 2025, 63:200-9. 10.1016\/j.resinv.2024.12.017","journal-title":"Respir Investig"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s13577-024-01063-0","article-title":"A xenotransplantable malignant deciduoid mesothelioma-cell line, D-Meso-Sonobe","volume":"37","author":"Hanamatsu Y","year":"2024","unstructured":"Hanamatsu Y, Saigo C, Sonobe H, Takeuchi T. A xenotransplantable malignant deciduoid mesothelioma-cell line, D-Meso-Sonobe. Hum Cell. 2024, 37:1226-8. 10.1007\/s13577-024-01063-0","journal-title":"Hum Cell"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/389327-a-rare-case-of-pleural-deciduoid-mesothelioma-with-histological-immunohistochemical-fluorescent-in-situ-hybridization-and-ultrastructural-findings","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:18:19Z","timestamp":1784956699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/389327-a-rare-case-of-pleural-deciduoid-mesothelioma-with-histological-immunohistochemical-fluorescent-in-situ-hybridization-and-ultrastructural-findings"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.113332","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,24]]}}}